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Abstract
Background: Contingency management (CM) is an evidence-based intervention providing tangible rewards as
positive reinforcement for abstinence from stimulants such as methamphetamine. Integrative approaches targeting
affect regulation could boost the effectiveness of CM in community-based settings and optimize HIV/AIDS
prevention efforts.
Methods/Design: This randomized controlled trial with HIV-positive, methamphetamine-using men who have sex
with men (MSM) is examining the efficacy of a 5-session, individually delivered positive affect regulation
intervention – Affect Regulation Treatment to Enhance Methamphetamine Intervention Success (ARTEMIS). ARTEMIS
is designed to sensitize individuals to non-drug-related sources of reward as well as assist with managing
depression and other symptoms of stimulant withdrawal during CM. HIV-positive, methamphetamine-using MSM
who are enrolled in a community-based, 12-week CM program are randomized to receive ARTEMIS or an attention-
matched control condition. Follow-up assessments are conducted at 3, 6, 12, and 15 months after enrollment in
CM. Four peripheral venous blood samples are collected over the 15-month follow-up with specimen banking for
planned biomarker sub-studies. The primary outcome is mean HIV viral load. Secondary outcomes include: sustained
HIV viral suppression, T-helper cell count, psychological adjustment, stimulant use, and potentially amplified
transmission risk behavior.
Discussion: Implementation of this randomized controlled trial highlights the importance of delineating boundaries
between research activities and community-based service provision. It also provides insights into best practices for
integrating the distinct agendas of academic and community partners in clinical research. This trial is currently enrolling
and data collection is anticipated to be completed in September of 2018.
Trial registration: This trial was registered on clinicaltrials.gov (NCT01926184) on August 16, 2013.
Keywords: Contingency management, Resilience, Men who Have Sex with men, Methamphetamine, HIV/AIDS,
Positive affect
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Background
There is increasing recognition that individuals who use
stimulants such as cocaine, crack, or methamphetamine
experience profound HIV-related health disparities [1].
HIV-positive men and women who use stimulants dis-
play substantially elevated HIV viral load, which appears
to be primarily due to difficulties with anti-retroviral
therapy (ART) adherence and persistence [2–4]. Conse-
quently, HIV-positive men and women who engage in
more frequent stimulant use are at elevated risk for fas-
ter HIV disease progression [5–7]. The co-occurrence of
elevated HIV viral load and HIV transmission risk be-
havior among HIV-positive, stimulant-using men who
have sex with men (MSM) also results in amplified risk
of onward HIV transmission [8, 9]. As a result, there is
increasing interest in testing substance abuse interven-
tions with HIV-positive, stimulant-using MSM with the
goal of increasing rates of sustained HIV viral suppres-
sion to optimize the effectiveness of HIV treatment as
prevention [10, 11].
Contingency management (CM) is an evidence-based,
behavioral intervention where individuals receive tan-
gible reinforcement for biologically confirmed substance
abstinence that has been tested as a stand-alone inter-
vention and shown to boost the effectiveness of cognitive-
behavioral therapy with stimulant users [12, 13]. Although
randomized controlled trials (RCTs) provide support for
the efficacy of CM for decreasing stimulant use among
substance-using MSM [14, 15], the effects are moderate
and not consistently sustained over long-term follow-up.
Similarly, a previous RCT with HIV-positive opiate and
cocaine users observed decreases in HIV viral load as well
as HIV risk behaviors immediately following CM, but
these were not maintained over follow-up [16]. These
short-term benefits may be partially attributable to the
difficulties individuals can experience with achieving
abstinence during CM [17] and the underscore the
need for more intensive treatment with those who have
chronic, relapsing substance use disorders [18]. In San
Francisco, the Department of Public Health has been
successfully implementing a 12-week CM intervention
with methamphetamine-using MSM since 2004 as one
component of more comprehensive substance abuse
treatment services tailored for MSM [19–21].
Novel approaches are needed to assist
methamphetamine-using MSM with managing symp-
toms of stimulant withdrawal that potentially under-
mine the effectiveness of CM. Negative reinforcement
models of addiction [22] highlight that increases in
depression and other forms of negative affect during
withdrawal are a potent, chronic stressor that can
serve as a trigger for stimulant use in MSM [23].
Consequently, interventions that provide coping skills
training and promote psychological resilience could
boost and extend the effectiveness of CM. Informed
by Revised Stress and Coping Theory, positive affect
(e.g., happiness, gratitude) may reinvigorate coping ef-
forts in the midst of chronic stress and build support-
ive social networks that assist individuals with managing
stressful circumstances [24, 25]. Lending support to its po-
tential adaptive significance, positive affect is associated
with decreased sexual risk taking behavior in MSM and
enhanced HIV disease management [26–28]. These find-
ings are generally consistent with the beneficial associa-
tions of positive affect with health and well-being in other
populations [29], but important questions remain regard-
ing whether this reflects personality factors or if the ex-
perience of more frequent positive affect is linked to
better outcomes [30].
Positive affect interventions could boost the effective-
ness of existing approaches to promote health behavior
change, and more clinical research is needed with HIV-
positive substance users. One RCT with hypertensive
African Americans observed that a positive affect inter-
vention delivered with patient education increased
medication adherence at 12 months compared to pa-
tient education alone, but no concurrent intervention-
related effects on blood pressure were observed [31].
Similarly, another RCT with patients receiving a percu-
taneous coronary procedure observed that a positive
affect intervention delivered with patient education in-
creased physical activity by almost 2-fold at 12 months
compared to patient education alone [32]. Among those
with alcohol and substance use disorders, positive affect
interventions may increase responsivity to non-substance-
related sources of reward, sustain cognitive-behavioral
change processes that are relevant to recovery, and help
build social relationships that are crucial to reducing or
avoiding substance use [33, 34]. One pilot RCT of a web-
based gratitude intervention with individuals receiving
outpatient treatment for an alcohol use disorder observed
short-term increases in low activation positive affect com-
pared to an attention-control condition [35]. We also
completed a pilot RCT with methamphetamine-using
MSM where a positive affect intervention delivered during
CM achieved short-term increases in positive affect
compared to CM alone [36]. Building upon this forma-
tive clinical research, we present the protocol for a
Phase II RCT of a positive affect intervention designed
to serve as an adjuvant to CM with HIV-positive,
methamphetamine-using MSM.
Method and design
This Phase II RCT is examining the efficacy of a 5-session
positive affect intervention that is designed to boost and
extend the effectiveness of CM with HIV-positive,
methamphetamine-using MSM (www.clinicaltrials.gov;
NCT01926184). All enrolled participants are referred to a
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community-based, 12-week CM program that must be ini-
tiated prior to randomization. CM visits are completed
at the San Francisco AIDS Foundation and all other
trial-related activities occur at a separate field site in
the community. Screening and enrollment are antici-
pated to continue through June of 2017 and follow-up
assessments will be completed in September of 2018.
All relevant procedures are approved by the Institu-
tional Review Boards for the University of California,
San Francisco and Northwestern University, and this
RCT received a certificate of confidentiality from the
National Institute on Drug Abuse. The data safety and
monitoring plan is overseen by the University of California,
Los Angeles Data Safety and Monitoring Board for
Addiction Medicine, which holds annual meetings to
review participant-related events and overall progress
for this RCT.
Recruitment, screening, and enrollment for the RCT
HIV-positive, methamphetamine-using MSM are re-
cruited for this RCT through three primary sources.
First, men initiating services at a community-based CM
program complete a brief consent form to be contacted
by study staff to learn more about the RCT. Second, dir-
ect recruitment is conducted using flyers and palm cards
that are distributed in HIV medical clinics, AIDS service
organizations, bars and clubs, bath houses, and via social
media. Third, an incentivized snowball sampling method
is employed where eligible participants receive a max-
imum of $30 for referring up to three individuals who
are subsequently judged to be eligible for the RCT.
To be eligible for this RCT, participants must meet the
following inclusion criteria: 1) 18 years of age or older;
2) identify as a MSM; 3) provide documentation of HIV-
positive serostatus (i.e., letter of diagnosis or ART medi-
cations other than Truvada that are matched to their
photo identification); and 4) provide a urine or hair sam-
ple that is reactive for methamphetamine metabolites.
All potentially eligible participants referred from the
community-based CM program are scheduled for an in-
person screening visit. Participants recruited from other
sources are required to report methamphetamine use in
the past 30 days to be eligible for an in-person screen-
ing visit.
At the in-person screening visit, participants complete
a signed informed consent, consent for specimen bank-
ing, a detailed tracking form with at least one secondary
contact, and a consent to search relevant death registries.
Participants also complete a Health Insurance Portability
and Accountability Act (HIPAA) release to access treat-
ment records at the CM program. Those who provide a
urine sample that is reactive for methamphetamine or
have documented evidence of a reactive urine screen for
methamphetamine from the CM program are immediately
scheduled for a baseline assessment. Those without evi-
dence or recent methamphetamine use from urine screen-
ing provide a hair sample for toxicology testing. Hair is
collected from the occipital region of the scalp where pos-
sible, but it is also collected from other sites (i.e., beard,
body) where necessary to obtain biological confirmation
of recent methamphetamine use. After the screening visit,
participants receive a $50 pre-loaded debit card. Partici-
pants are excluded after the screening visit for the follow-
ing reasons: 1) prescription of a psychostimulant (e.g.,
Adderall) that cross reacts with urine screening for meth-
amphetamine; 2) inability to provide informed consent; 3)
unable to follow the study protocol; and 4) judged by the
principal investigators that it is not in the best interests of
the individual to participate.
Community-based CM program
This RCT is being conducted in partnership with a
community-based, 12-week CM program for
methamphetamine-using MSM that is operated by
the San Francisco AIDS Foundation. Individuals who
are interested in the CM program complete a de-
tailed intake that includes assessments of the fre-
quency with which they use methamphetamine and
engage in sexual behaviors with men. MSM who re-
port using methamphetamine at least weekly on
average in the past three months provide a urine
sample for toxicology screening at the intake visit
and are enrolled in the CM program irrespective of
urine toxicology results.
All clients in the CM program are encouraged to pur-
sue abstinence from methamphetamine and other stimu-
lants during the 12-week CM period. Urine sample
collection is directly observed by CM program staff. The
voucher for the initial sample that is negative for meth-
amphetamine and cocaine metabolites is worth $2.00.
Vouchers increase in value by 25 cents for each con-
secutive stimulant-free sample to a maximum of $10.00.
Participants earn an $8.50 bonus voucher for every third
consecutive stimulant-free sample. A rapid reset proced-
ure allows participants to return to their place in the es-
calating reinforcement schedule after producing three
consecutive urine samples that are non-reactive for
methamphetamine and cocaine [19]. The total possible
reinforcement is $330, and participants may choose to
receive incentives earned any time during or after the
12-week CM intervention period.
Concurrent with the CM urine screening visits, clients
may participate in a drop-in group that provides social
support for continuing to pursue goals for stimulant use
reduction or abstinence. Drop-in groups also provide
opportunities to facilitate linkage to community-based
services including formal substance abuse treatment and
HIV care. After completing the 12 weeks of urine
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screening visits, individuals are invited to attend after-
care sessions to continue to forge social networks that
are supportive of avoiding stimulant use and develop re-
lapse prevention plans. Those who complete the 12-
week CM program with aftercare are invited to continue
attending regular drop-in groups to provide support and
mentorship to men who are actively completing the
thrice weekly urine screening visits.
Run-in period and randomization
All eligible participants complete a run-in period where
they are required to complete five separate visits prior to
randomization. These visits include: 1) a baseline assess-
ment with a peripheral venous blood sample; 2) three
urine screening visits (regardless of the toxicology re-
sults) at the community-based CM program; and 3) a
separately scheduled randomization visit where the first
intervention or attention-control session is administered.
Participants who fail to complete the run-in period are
not randomized and do not complete subsequent visits
for this RCT unless at some point they re-initiate con-
tact with the study team and choose to be re-screened.
Randomization is accomplished using a computer gener-
ated sequence with randomly permuted block sizes of 2,
4, and 6 to guard against subversion. Only the study data
manager has access to the computer-based randomization
algorithm. Because randomization occurs at the first inter-
vention or attention-control session, this ensures that all
participants in this RCT complete at least one of the five
individually delivered sessions.
Positive affect intervention
Affect regulation treatment to enhance methampheta-
mine intervention success (ARTEMIS) is a multi-
component, individually-delivered 5-session intervention
targeting positive affect regulation. This intervention
was adapted from prior clinical research testing the
feasibility and acceptability of a positive affect interven-
tion for recently diagnosed HIV-positive persons [37].
The extant positive affect intervention protocol was
adapted and pilot tested in a RCT with 21
methamphetamine-using MSM receiving CM [36].
Based on the results of the pilot RCT, the positive
affect intervention protocol was further refined prior
to initiating the present Phase II RCT with HIV-
positive, methamphetamine-using MSM.
The original positive affect intervention protocol con-
sists of eight skills:
(1) positive event noting; (2) positive event capitalizing;
(3) gratitude; (4) informal and formal mindfulness; (5)
positive reappraisal; (6) personal strengths; (7) attainable
goals; and (8) acts of kindness. As shown in Table 1, we
modified the original protocol to tailor this positive
affect intervention for HIV-positive, methamphetamine-
using MSM. These adaptations included additional con-
tent to optimize delivery of the core positive affect regu-
lation skills with this population and new components
designed to facilitate greater engagement in the recovery
process (e.g., problem-focused coping, values clarifica-
tion, and referral to community-based services). In-
formed by prior research examining the efficacy of
mindfulness-based relapse prevention [38–40], partici-
pants also complete meditation exercises during ARTEMIS
intervention sessions to further enhance metacognitive
awareness and assist individuals in coping more effectively
with methamphetamine withdrawal. Self-report measures
of stimulant craving before and after each session as well
as a measure of positive and negative affect before sessions
one, three, and five are completed by participants. Partici-
pants can choose to receive $20 in cash per session or two
$50 debit cards upon completion of all five sessions,
complete detailed home practice exercises, receive a work-
book with each of the skills outlined and an iPod shuffle
that is pre-loaded with meditation exercises to facilitate
regular practice.
Session one begins with an overview of the interven-
tion and psychoeducation about the stressful nature of
stimulant withdrawal that individuals experience during
CM. Positive affect regulation skills are framed as one
way of more effectively coping during this stressful
period. Participants are encouraged to start by noticing
positive events that occur in daily life and explore ways
to amplify or extend the experience of positive emo-
tions related to these events (i.e., capitalizing). In
addition to identifying positive events in their daily
Table 1 Positive affect intervention protocol for HIV-positive,
methamphetamine-using MSM
Session Positive Affect Regulation
Skills
Additional Intervention
Content
1 Noticing Positive Events Psychoeducation on Stimulant
Withdrawal
Capitalizing on Positive
Events
Capitalizing on Non-Reactive Urine
Toxicology
Gratitude Breathing Retraining with Positive
Event Imagery
2 Mindfulness (Informal
and Formal)
Breath Meditation
Self-Compassion
3 Positive Reappraisal Problem-Focused Coping &
Reasoned Action
Breath Meditation
4 Strengths Values Clarification
Attainable Goals Mountain Meditation
5 Altruism Volunteer opportunities
Linkage to More Intensive
Community-Based Services
Loving Kindness Meditation
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lives, participants are asked to describe positive emo-
tions that stem from having a urine screen during CM
that was non-reactive for stimulants (where applicable)
and continue to capitalize on this positive event. The
concept of gratitude as a feeling of appreciation or
thankfulness that can stem from positive events is also
introduced. Finally, facilitators deliver a modified breath-
ing retraining exercise that includes positive event imagery
to assist participants with capitalizing on a positive event
in vivo. For home practice, participants are asked to
complete the “One Good Thing” exercise where they note
a positive event that happened each day and briefly de-
scribe responses to the event. Participants are also asked
to begin keeping a gratitude journal that continues
throughout the 5-session intervention [41].
Session two includes mindfulness-based skills training
to cultivate non-judgmental, present-centered awareness.
By facilitating metacognitive awareness, mindfulness pro-
motes greater insight into cognitive and emotional re-
sponses to events which may reduce craving and decrease
the likelihood that individuals engage in the overlearned
response of substance use [39]. Informal mindfulness ex-
ercises are completed in-session to encourage individuals
to develop an enhanced awareness of daily experiences
(e.g., brushing one’s teeth). Participants also complete a
brief formal mindfulness-based meditation practice (i.e.,
breath awareness) and receive an iPod shuffle preloaded
with three meditation exercises: breath awareness, moun-
tain meditation and loving kindness meditation [42]. Fi-
nally, this session concludes with a discussion of the
importance of self-compassion as a way of coping with
stressful life circumstances. Participants are encouraged to
be more tolerant of their imperfections by developing a
supportive and caring self-orientation. Home practice in-
cludes informal mindfulness practice (i.e., “Practicing Be-
ing Present in Daily Life” exercise), formal mindfulness
meditation using the iPod shuffle, and the gratitude jour-
nal. Participants may listen to any of the three recordings
on the iPod shuffle.
Session three focuses on executing effective coping re-
sponses. Participants are introduced to the concept of
positive reappraisal whereby individuals change their in-
terpretations of stressful events to support successful
adaptation. The facilitator reviews ways in which chan-
ging thoughts about a stressful event (i.e., positive reap-
praisals) can affect emotional responses and subsequent
behaviors. This is generally consistent with the approach
of cognitive-behavioral treatments like the Matrix Model
[43], but there is no requirement that the initial ap-
praisal of an event is distorted. Especially where aspects
of a stressful event are uncontrollable, participants are
encouraged to examine ways in which the experience
could have been worse or how they learned something
new as a result of enduring this stressful event (both
examples of positive reappraisals). Participants are asked
to identify a recent stressful event and work with the fa-
cilitator to practice different methods for positive re-
appraisal in session.
Another important component of session three is
reviewing methods of enhancing coping effectiveness in
response to controllable situations [44, 45]. Where aspects
of stressful circumstances are controllable, participants
are encouraged to explore problem-focused coping strat-
egies that can be implemented to reduce the experience of
stress. Participants briefly review possible problem-
focused coping strategies with the facilitator. This process
of executing effective coping responses by engaging in
positive reappraisal and then problem-focused coping is
presented as “reasoned action” where managing emotional
responses to an event is a critical first step towards ad-
dressing any aspects that are within one’s control. Par-
ticipants also complete a formal mindfulness-based
meditation practice (i.e., breath awareness) at this ses-
sion. Home practice includes daily positive reappraisal
exercises where participants identify stressful events,
develop positive reappraisal(s), and delineate concrete
actions that can be taken to address the identified
‘problem.’ Participants also continue with the medita-
tion practice and the gratitude journal.
Session four begins with an exercise where participants
are asked to reflect on personal strengths. This process
promotes greater insight into personal sources of resili-
ence and enhances self-affirmation, which has been
linked to enhanced problem solving and self regulation
[46, 47]. After identifying personal strengths, partici-
pants are asked to examine the degree to which these
strengths are linked to personal values or the ways in
which strengths assist one with living values in action.
Then, participants are introduced to the concept of at-
tainable goals, which are presented as short-term goals
that are Achievable, have Clear steps, and a definitive
Endpoint (ACE). Strengths and values are presented as
important resources that energize goal-oriented pro-
gress. Participants are encouraged to examine ways in
which leveraging personal strengths could facilitate
progress toward attainable goals. Values are framed as
the underlying meaning structures that remind individ-
uals why attainable goals are important. This session
concludes with the mountain meditation which focuses
on embracing personal strengths and resilience in the
midst of stress [42]. For home practice, participants are
asked to monitor progress towards completing attain-
able goals identified in session while noting personal
strengths that assist with progress toward these goals.
Participants also continue with the meditation practice
and the gratitude journal.
Session five targets altruism by discussing findings that
small acts of kindness may enhance psychological
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adjustment and bolster physical health [48, 49]. Partici-
pants review ways in which they can incorporate small
acts of kindness into their daily activities and review for-
mal volunteer opportunities available in the community.
Participants also complete the loving kindness medita-
tion [42], which focuses on experiencing feelings of love
and caring toward another person. The facilitator also
leads the participant through a thorough skills review
of all the positive affect and coping skills delivered
throughout the five sessions. This portion of the inter-
vention focuses on discussing positive aspects of the
ARTEMIS sessions for the participant and ways in
which he can continue to pursue treatment in the com-
munity. Tailored referrals are provided to assist partici-
pants with engaging in more intensive mental health or
substance abuse treatment.
Attention-control condition
The attention-control consists of five sessions that in-
clude face-to-face administration of psychological mea-
sures and neutral writing exercises [50]. Participants are
instructed to write as if they were reporting facts with-
out going into any of the thoughts or feelings about the
events (e.g., plans for the next 24 h). All sessions are
comparable in length to the intervention sessions, but
do not include any skills practice. Self-report measures
of stimulant craving before and after each session as well
as a measure of positive and negative affect before ses-
sions one, three, and five are completed by participants.
Participants can choose to receive $20 cash for complet-
ing each attention-control session or two $50 debit cards
upon of the completion of the fifth session, and an iPod
with three preloaded pop songs.
Staff training and fidelity monitoring
Each staff member receives a detailed training on assess-
ment protocols for this RCT: 1) privacy and confidential-
ity including HIPAA security practices and human
subjects protection training; 2) obtaining informed con-
sent; 3) blood borne pathogens training 4) safe shipping
of biological specimens training 5) laboratory safety for
researchers training 6) technology training including use
of laptops for data collection and the participant data-
base; 7) interviewing techniques such as building rap-
port, working with diverse populations, cultural sensitivity,
population-specific issues and referrals, maintaining confi-
dentiality, basic quantitative and qualitative interview
skills; 8) a detailed suicidality assessment protocol; and 9)
and role playing of assessments or individual sessions.
Intervention facilitators are provided with a detailed
manual that describes the procedures for administering
the five individual intervention sessions. Facilitators con-
ducted mock sessions and the audio recordings of these
sessions are reviewed by a clinical supervisor who then
meets one-on-one with the facilitator to provide feed-
back on delivery of intervention content and process-
oriented techniques. Mock sessions are repeated until
the facilitator is judged to be competent with each of the
five intervention sessions.
The protocol for monitoring the fidelity of the positive
affect intervention sessions during the course of the
study includes audio recording of sessions for weekly re-
view with a clinical supervisor and fidelity checklist rat-
ings that are reviewed monthly in group supervision.
Audio recordings of intervention sessions are reviewed
by the fidelity monitor and the clinical supervisor to as-
sess adherence to the protocol, delivery, interpersonal
skills, rapport, and session flow. Approximately 10 % of
all positive affect intervention sessions are coded using
fidelity rating checklists with detailed feedback provided
to facilitators.
Follow-up assessments and specimen banking
At 3, 6, 12 and 15 months after enrollment in CM, each
participant completes computer-based follow-up assess-
ments that are administered by a trained interviewer
who has not administered intervention or attention-
control sessions to that participant. Self-reported sub-
stance use and sexual behavior measures are completed
by participants using audio computer-assisted self-
interviewing to enhance reliability and validity [51].
Urine samples for on-site toxicology testing for recent
use of methamphetamine, cocaine, opiates, marijuana,
and benzodiazepines (Redwood Biotech iCup®; Santa
Rosa, CA) are collected at each assessment. Peripheral
venous blood samples are collected at baseline as well as
6, 12, and 15 months following enrollment in CM to
measure HIV viral load and CD4+ T-cell count. Partici-
pants receive a pre-loaded $50 debit card for completing
each of the assessment visits over the 15-month period.
Participants are also asked to provide an additional
25 ml of peripheral venous blood using two 10 mL
EDTA and two 5 mL PAXgene® tubes (Qiagen, Inc.) at base-
line as well as 6, 12, and 15 months following enrollment in
CM. Using EDTA tubes, leukocyte DNA is extracted and
banked. Approximately three mL of plasma are also banked.
PaXgene® tubes are used for isolation and stabilization of
RNA. These tubes are progressively frozen and banked.
Primary and secondary outcome measures
HIV viral load
HIV viral load testing is performed to detect plasma
HIV RNA using the Abbott RealTime HIV-1 assay
(Abbott Molecular, Inc.; Des Plaines, IL). Although this
assay has a lower limit of detection of 40 copies/mL,
valid viral load values below this level are observed
with less reliable frequency [52]. The primary outcome
for this RCT is change in mean log10 HIV viral load.
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Sustained HIV viral suppression, defined as an undetect-
able HIV viral load (<40 copies/mL) over the 15-month
follow-up, will be examined as a secondary outcome.
CD4+ T-cell count
CD4+ T-cell count is measured with whole blood using
flow cytometry. CD4+ assays are performed by Quest
Diagnostics.
ART adherence and persistence
At each assessment, participants currently taking ART
medications are asked to rate their adherence to each
medication during the past 30 days using the visual
analogue scale [53]. Participants are also asked to indi-
cate if they have experienced a treatment interruption, a
period of two days or more where all HIV medications
were stopped without guidance from an HIV primary
care provider. Using these measures, a composite index
of ART adherence and persistence will be calculated by
summing the following indicators (1 point each): 1) cur-
rently on ART; 2) no treatment interruption in the past
six months; and 3) 100 % self-reported ART adherence
in the past 30 days.
Psychological adjustment
The Differential Emotions Scale (DES) is administered
to assess the frequency of positive and negative affect
during the past week [54]. Participants rate how fre-
quently they felt a particular emotion during the past
week. The DES measures high and low level intensity
positive and negative affect, which will be examined as
separate outcomes. The Center for Epidemiological Stud-
ies Depression Scale (CES-D) is administered to measure
symptoms of depression during the past week [55, 56].
Stimulant craving
The Penn Alcohol Craving Scale is a five-item self-
report measure that was adapted for assessment of
methamphetamine craving [57]. Frequency, intensity,
and duration of thoughts about using methamphetamine
are assessed at each assessment visit. Immediately before
and after each individual session (i.e., ARTEMIS inter-
vention or attention-control), participants also rate the
intensity of their current craving for methamphetamine,
powder cocaine, and crack cocaine separately using a
visual analogue scale from zero (no craving at all) to 100
(some of the worst craving ever).
Stimulant use
Participants report how often they have used various
substances in the past three months. Participants who
have used a given substance in the past three months
are asked to report the number of days they used that
substance in the past 30 days, which is consistent with
Addiction Severity Index [58]. Participants also report
the longest number of days in a row they used each sub-
stance in the past 30 days to index binge use [59]. Fi-
nally, those who provide a urine sample that is reactive
for methamphetamine or cocaine (1) will be compared
to those who provide a urine sample that is not reactive
for these stimulants (0).
Potentially amplified transmission risk behavior
Participants report the number of anal sex partners in
the past 3 months, stratified by whether or not they were
feeling the effects of methamphetamine [21]. The total
number of condomless HIV-negative or unknown serosta-
tus partners is calculated, stratified by methamphetamine
use. Potentially amplified transmission risk partners are
the number of condomless anal sex partners who are
HIV-negative or unknown serostatus where participants
have a HIV viral load greater than 200 copies/mL at the
same assessment visit. The total number of potentially
amplified transmission risk partners stratified by metham-
phetamine use will be calculated. We will also examine
any engagement in any potentially amplified transmission
risk as an outcome.
Outcome analyses
We will first generate one-way frequency tables for all
variables and measures of central tendency and variabil-
ity for continuous variables (e.g., means, medians, stand-
ard deviations) to perform range checks, quantify the
amount of missing data, and yield valuable descriptive
findings. Chi-square tests, t-tests, and comparable two-
group non-parametric tests will be used to investigate
equality of potential confounders (e.g., homelessness)
across the intervention and attention-control conditions
at baseline. Similarly, we will confirm that there are no
differences in the mean number of intervention and
attention-control sessions completed as well as no differ-
ential attrition by study arm.
Based on our extensive experience working with this
population, we anticipate a maximum of 20% attrition
over the 15-month investigation period. Attrition ana-
lyses will compare respondents who complete all mea-
surements to those who do not based on baseline
characteristics and we will test for differential attrition
by intervention condition. Direct maximum likelihood
and multiple imputation will be used to address incom-
plete data because these methods make the relatively
mild assumption that missing data arise from a condi-
tionally missing-at-random process [60].
Intent-to-treat analyses will be conducted primarily
using multilevel random coefficient models (i.e., hier-
archical linear modeling; HLM). These models incorpor-
ate random intercepts and slopes for each participant
based on the participant’s multiple measurements over
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time [61]. Initial models will be unadjusted and compare
outcome trajectories for participants in ARTEMIS +CM
and Attention-Control + CM across time via the group-by-
time interaction effect. If preliminary analyses detect imbal-
ance in potential confounders across the groups that can-
not be satisfactorily addressed via covariate adjustment, we
will substitute causal inference methods based on the
Rubin causal model (e.g., propensity score weighting; mar-
ginal structural models) to obtain population-level effects
of the intervention under the assumption of balanced con-
founders between the two groups [62–66]. A priori planned
comparisons will be performed to test group differences at
3, 6, 12, and 15 months for both the primary and secondary
outcomes. These planned comparisons will be evaluated at
α = .05; any subsequent post-hoc comparisons will be ad-
justed via simulation-based stepdown methods to maintain
a nominal Type I error rate of .05 [67].
The primary outcome will be log10 HIV viral load over
the 15-month follow-up. Sustained HIV viral suppres-
sion will be examined as a secondary outcome using lo-
gistic regression of the binary outcome of sustained
virologic suppression over the 15-month follow-up (0 =
no; 1 = yes) on randomization group assignment. Other
continuous secondary outcomes that will be examined
in intent-to-treat analyses include: CD4+ T-cell count,
positive and negative affect, stimulant craving, and self-
reported stimulant use. Ordered categorical and categor-
ical outcomes assessed repeatedly over the 15-month
follow-up include: ART adherence and persistence, a
positive urine toxicology result for stimulants, poten-
tially amplified transmission risk partners stratified by
methamphetamine use, and any potentially amplified
transmission risk.
Power analysis
Using NCSS PASS with a total sample size of 150, 80 %
retention, and four repeated measures of viral load, the
minimum detectable effect sizes are in the small-
medium range (Cohen’s d = 0.29–0.47). Estimates of the
minimum detectable effect size vary depending on the
within-subject correlation. Overall, this RCT has ad-
equate power to detect moderate effects of ARTEMIS +
CM on the primary outcome, log10 HIV viral load.
Discussion
Informed by Revised Stress and Coping Theory, positive
affect is thought to serve unique, adaptive functions in
the midst of chronic stress because it sustains coping
efforts and builds personal resources for coping with
stress [24, 25]. Among those with alcohol or substance
use disorders, positive affect may sensitize individuals
to non-substance-related sources of reward, sustain
cognitive-behavioral change processes that are relevant
to recovery, and help build social relationships that are
supportive reducing or avoiding substance use [33, 34].
There is also increasing recognition that positive affect
is associated with HIV-related health behavior change
[26–28], and positive affect interventions may optimize
the effectiveness of health education in other patient
populations [31, 32]. This RCT is among the first to
test the efficacy of a positive affect intervention de-
signed to boost and extend the effectiveness of CM
with HIV-positive, methamphetamine-using MSM.
Prior research observed that CM is effective for redu-
cing HIV viral load in the short-term [16], and integra-
tive approaches may be needed to achieve sustained
decreases in HIV viral load. By examining log10 HIV viral
load as the primary outcome as well as sustained HIV
viral suppression and CD4+ T-cell count as secondary
outcomes, our team will be able to index whether a posi-
tive affect intervention delivered with CM can achieve
meaningful improvements in HIV disease markers com-
pared to CM alone. To our knowledge, only two prior
RCT’s of cognitive-behavioral interventions with
methamphetamine-using MSM observed reductions in
condomless anal intercourse, which were modest and
not consistently maintained over follow-up [15, 68].
Novel approaches for HIV-positive, methamphetamine-
using MSM are needed to reduce viral load in this popu-
lation in order to mitigate risk of onward HIV transmis-
sion and optimize health outcomes. In the present RCT,
any effects of ARTEMIS + CM on HIV viral load could
be attributable to the effects of enhanced psychological
adjustment and reduced stimulant use on greater ART
adherence and persistence. These mediating pathways
will be examined to better understand any underlying
mechanisms whereby ARTEMIS + CM may optimize the
effectiveness of HIV treatment as prevention.
One important strength of this RCT is that it requires
biological confirmation of recent methamphetamine use,
which has not been part of the inclusion criteria for
prior RCTs of CM with this population [14, 15, 17]. Bio-
logical confirmation of recent methamphetamine use
maximizes internal validity by ensuring that participants
are not merely reporting methamphetamine use to re-
ceive incentives from the CM program as well as study-
related visits. On the other hand, it introduces concerns
that community members may become aware of the in-
clusion criteria and use methamphetamine to be eligible.
In order to successfully implement this RCT, our team
has gone to great lengths to conceal inclusion criteria by
not referring directly to methamphetamine use in any
recruitment materials, conducting an extensive screen-
ing visit with multiple assessment measures to conceal
inclusion criteria, and refraining from engaging discus-
sions of the inclusion criteria with those who are not eli-
gible. At the same time, requiring biological confirmation
of recent methamphetamine use has presented challenges
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for achieving enrollment targets. We have been unable to
collect hair from the scalp for some men to establish that
they meet the inclusion criteria, and hair from other body
sites is not an optimal indicator of recent methampheta-
mine use [69]. There are also individuals who have
achieved early partial abstinence that are at risk of relapse,
but we are unable to enroll these participants because we
cannot obtain biological confirmation of recent metham-
phetamine use. Further advances in methamphetamine
toxicology screening are needed to optimize clinical re-
search with substance-using populations.
CM for this RCT is delivered by a community-based
program, which has introduced a number of opportun-
ities and challenges. The overall objectives of this RCT
are substantially supported by leveraging an established
and well respected CM program in the community for
methamphetamine-using MSM. Specifically, our rela-
tionship with a community-based CM program substan-
tially supported our efforts to refine and deliver the
ARTEMIS intervention as well as enhanced our recruit-
ment and retention efforts. At the same time, there are
challenges with navigating the enrollment goals of this
RCT with the relatively large number of men seeking
CM services, only a subset of who are eligible for this
RCT. Because the CM program strives to provide ser-
vices on demand and without regard to HIV status, con-
ducting this RCT has led to substantial increases in the
number of men receiving services to maximize the num-
ber of participants who meet criteria for randomization.
Due to the popularity of this CM program, we have ex-
perienced difficulties with reserving space for individuals
who meet our inclusion criteria, thus creating a tension
between the enrollment target for the RCT and clinical
service delivery. Navigating these challenges has required
ongoing discussions to integrate the distinct agendas of
the academic and community partners.
Conducting a community-engaged RCT with a CM
program has also required a greater focus on clearly de-
lineating roles and responsibilities. Although participants
complete a HIPAA release to allow for communications
with the CM program, this is for the expressed purpose
of establishing eligibility for randomization, to extract
the CM urine screening results and CM incentives re-
ceived from the clinical records, and assist with tracking
for follow-up. Due to our close and ongoing interactions
with the CM program, the research team must avoid dis-
cussions that are relevant to the clinical care participants
are receiving in the CM program and strive to disclose
only the minimum information necessary to CM pro-
gram staff regarding each participant’s study activities.
Similarly, our close connection with the CM program
can create role confusion for participants that contrib-
utes to a therapeutic misconception [70]. This requires
staff to have detailed and ongoing discussions with
participants about the distinctions between participating
in this RCT and receiving clinical services. Staff note
their ethical obligation to ensure the safety of partici-
pants, conducting detailed screenings for suicidal or
homicidal ideation, plan, and intent where necessary.
However, participants often present with other acute
stressors such as food insecurity and housing instability
that are beyond the scope of the role of research staff. In
these instances, participants are provided with a detailed
referral sheet and encouraged to seek out clinical staff at
the CM program where appropriate.
ARTEMIS acknowledges that not all HIV-positive,
methamphetamine-using MSM are ready, willing, or able
to abstain from stimulant use. The focus of ARTEMIS
on positive affect and non-substance-related sources of
reward challenges the dominant paradigms of addiction
treatment because it does not directly target psycho-
logical processes such as motivation that are traditionally
conceptualized as being most relevant to reducing sub-
stance use. Instead, the positive affect intervention is de-
signed to build the capacity of participants to cope more
effectively with depression and other symptoms of
stimulant withdrawal, which could maximize success
with stimulant abstinence during CM and boost the
long-term effectiveness of CM.
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